Warrior CARE: Naturalistic Observation and Harm Reduction

Post Traumatic Stress Disorder Clinical Trial

— NOC  

Official title:

Wayne Warrior CAnnabis Research and Education: Naturalistic Observation and Harm Reduction

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05386862
• Other study ID #: Warrior CARE: NOC
• Status: Withdrawn
• Phase: N/A
• Start date: July 13, 2022
• Est. completion date: January 25, 2024

Study information

• Verified date: May 2024
• Source: Wayne State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is looking at therapeutic potential of reducing Tetrahydrocannabinol (THC) levels in regular cannabis smokers using contingency management (CM) intervention in a U.S. veteran population with post-traumatic stress disorder (PTSD).

Description:

In this trial, the investigators will recruit veterans with post-traumatic stress disorder (PTSD) who report using cannabis. Veterans will be assigned (via participant self-selection) into either a naturalistic group that will be followed as the participants continue to use cannabis as they normally do (observation only), or into a "THC (tetrahydrocannabinol) reduction group" in which veterans are asked to switch from their typical cannabis product to using a lower THC/higher Cannabidiol (CBD) product; adherence to this switch will be incentivized using a behavioral intervention called contingency management (CM).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 25, 2024
• Est. primary completion date: January 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 69 Years

Eligibility

Inclusion Criteria:

• able to provide informed consent, IQ Score >80,
• served in branch of the US armed forces, report using cannabis,
• report using cannabis (at least 4x/month)
• test positive for THC in urine drug screen,
• meet DSM-5 criteria for PTSD w/ Sx of at least 6 months duration

Exclusion Criteria:

• urine drug screen positive for any other drugs
• any clinically significant medical problems,
• any current or past serious psychotic or bipolar disorder diagnosis as determined by SCID-5
• at immediate high risk for suicide based on the C-SSRS
• current SUD other than Nicotine Use Disorder, Alcohol (mild or moderate) and Cannabis Use Disorder
• seeking treatment for Cannabis Use Disorder

Related Conditions & MeSH terms

• Cannabis Use
• Marijuana Abuse
• Post Traumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic
• Suicide

Intervention

Behavioral:
• Reduce THC Use
Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity

Locations

Country	Name	City	State
United States	Tolan Park Medical Building	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

References & Publications (41)

Abizaid A, Merali Z, Anisman H. Cannabis: A potential efficacious intervention for PTSD or simply snake oil? J Psychiatry Neurosci. 2019 Mar 1;44(2):75-78. doi: 10.1503/jpn.190021. No abstract available. — View Citation

Adkisson K, Cunningham KC, Dedert EA, Dennis MF, Calhoun PS, Elbogen EB, Beckham JC, Kimbrel NA. Cannabis Use Disorder and Post-Deployment Suicide Attempts in Iraq/Afghanistan-Era Veterans. Arch Suicide Res. 2019 Oct-Dec;23(4):678-687. doi: 10.1080/13811118.2018.1488638. Epub 2018 Nov 17. — View Citation

Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science. 1997 Feb 28;275(5304):1293-5. doi: 10.1126/science.275.5304.1293. — View Citation

Beck, A.T., Steer, R.A., & Brown, G.K. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.

BERG EA. A simple objective technique for measuring flexibility in thinking. J Gen Psychol. 1948 Jul;39:15-22. doi: 10.1080/00221309.1948.9918159. No abstract available. — View Citation

Bilgin M, Bindila L, Graessler J, Shevchenko A. Quantitative profiling of endocannabinoids in lipoproteins by LC-MS/MS. Anal Bioanal Chem. 2015 Jul;407(17):5125-31. doi: 10.1007/s00216-015-8559-8. Epub 2015 Mar 18. — View Citation

Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013 May-Jun;22(3):277-84. doi: 10.1111/j.1521-0391.2012.12018.x. — View Citation

Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994 Mar;23(2):129-38. — View Citation

deRoon-Cassini TA, Stollenwerk TM, Beatka M, Hillard CJ. Meet Your Stress Management Professionals: The Endocannabinoids. Trends Mol Med. 2020 Oct;26(10):953-968. doi: 10.1016/j.molmed.2020.07.002. Epub 2020 Aug 28. — View Citation

Ellis JD, Struble CA, Fodor MC, Cairncross M, Lundahl LH, Ledgerwood DM. Contingency management for individuals with chronic health conditions: A systematic review and meta-analysis of randomized controlled trials. Behav Res Ther. 2021 Jan;136:103781. doi: 10.1016/j.brat.2020.103781. Epub 2020 Nov 30. — View Citation

First MB, Williams JBW, Karg RS, Spitzer RL (2015) User's Guide for the Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5-RV). Arlington, VA, American Psychiatric Association

Frisch, M.B., Cornell, J., Villanueva, M. & Retzlaff, P.J. (1992). Clinical validation of the quality of life inventory: A measure of life satisfaction for treatment planning and outcome assessment. Psychological Assessment, 4, 92-101.

Gachet MS, Rhyn P, Bosch OG, Quednow BB, Gertsch J. A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 22;976-977:6-18. doi: 10.1016/j.jchromb.2014.11.001. Epub 2014 Nov 18. — View Citation

Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl). 2003 Jan;165(2):157-65. doi: 10.1007/s00213-002-1210-3. Epub 2002 Nov 19. — View Citation

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl). 1999 Feb;141(4):395-404. doi: 10.1007/s002130050849. — View Citation

Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, Hillard CJ, Yehuda R. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013 Dec;38(12):2952-61. doi: 10.1016/j.psyneuen.2013.08.004. Epub 2013 Sep 10. — View Citation

Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008 Mar;41(2):48-53. doi: 10.1055/s-2007-993211. — View Citation

Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540. — View Citation

Ledgerwood DM, Arfken CL, Petry NM, Alessi SM. Prize contingency management for smoking cessation: a randomized trial. Drug Alcohol Depend. 2014 Jul 1;140:208-12. doi: 10.1016/j.drugalcdep.2014.03.032. Epub 2014 Apr 13. — View Citation

Maples-Keller JL, Rauch SAM, Jovanovic T, Yasinski CW, Goodnight JM, Sherrill A, Black K, Michopoulos V, Dunlop BW, Rothbaum BO, Norrholm SD. Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders. J Anxiety Disord. 2019 Dec;68:102147. doi: 10.1016/j.janxdis.2019.102147. Epub 2019 Sep 21. — View Citation

Marczylo TH, Lam PM, Amoako AA, Konje JC. Anandamide levels in human female reproductive tissues: solid-phase extraction and measurement by ultraperformance liquid chromatography tandem mass spectrometry. Anal Biochem. 2010 May 15;400(2):155-62. doi: 10.1016/j.ab.2009.12.025. Epub 2009 Dec 22. — View Citation

Marczylo TH, Lam PM, Nallendran V, Taylor AH, Konje JC. A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. Anal Biochem. 2009 Jan 1;384(1):106-13. doi: 10.1016/j.ab.2008.08.040. Epub 2008 Sep 18. — View Citation

Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One. 2012;7(7):e42399. doi: 10.1371/journal.pone.0042399. Epub 2012 Jul 31. — View Citation

McDougle DR, Watson JE, Abdeen AA, Adili R, Caputo MP, Krapf JE, Johnson RW, Kilian KA, Holinstat M, Das A. Anti-inflammatory omega-3 endocannabinoid epoxides. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6034-E6043. doi: 10.1073/pnas.1610325114. Epub 2017 Jul 7. — View Citation

Milner, B. (1963). Effects of different brain lesions on card sorting. Archives of Neurology, 9, 90-100.

Norr AM, Smolenski DJ, Reger GM. Effects of prolonged exposure and virtual reality exposure on suicidal ideation in active duty soldiers: An examination of potential mechanisms. J Psychiatr Res. 2018 Aug;103:69-74. doi: 10.1016/j.jpsychires.2018.05.009. Epub 2018 May 12. — View Citation

Olenick M, Flowers M, Diaz VJ. US veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract. 2015 Dec 1;6:635-9. doi: 10.2147/AMEP.S89479. eCollection 2015. — View Citation

Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment. 2001 Dec;8(4):443-54. doi: 10.1177/107319110100800409. — View Citation

Petry NM, Alessi SM, Ledgerwood DM. A randomized trial of contingency management delivered by community therapists. J Consult Clin Psychol. 2012 Apr;80(2):286-98. doi: 10.1037/a0026826. Epub 2012 Jan 16. — View Citation

Petry NM, Alessi SM, Ledgerwood DM. Contingency management delivered by community therapists in outpatient settings. Drug Alcohol Depend. 2012 Apr 1;122(1-2):86-92. doi: 10.1016/j.drugalcdep.2011.09.015. Epub 2011 Oct 5. — View Citation

Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. — View Citation

Reid HH, Ledgerwood DM. Depressive symptoms affect changes in nicotine withdrawal and smoking urges throughout smoking cessation treatment: Preliminary results. Addict Res Theory. 2016;24(1):48-53. doi: 10.3109/16066359.2015.1060967. Epub 2015 Jun 26. — View Citation

Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. — View Citation

Watkins BA, Kim J, Kenny A, Pedersen TL, Pappan KL, Newman JW. Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets. Biochim Biophys Acta. 2016 Nov;1861(11):1693-1704. doi: 10.1016/j.bbalip.2016.07.007. Epub 2016 Jul 22. — View Citation

Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. — View Citation

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. doi: 10.1037/pas0000486. Epub 2017 May 11. — View Citation

Weathers, F.W., et al., The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). 2013, Washington DC: National Center for PTSD.

Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., & Schnurr, P.P. (2013). The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov.

Wechsler, D. (2009). Wechsler Memory Scale - 4th Edition. Pearson Assessments.

Zachary RA (1991) Shipley Institute of Living Scale: revised manual. Los Angeles: Western Psychological Services

* Note: There are 41 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Clinician-Administered PTSD Scale for DSM-5 Total Severity Score (CAPS-5)	Assessing change in PTSD symptom severity from baseline, to 3, 6, and 12 months post baseline. A decrease in the CAPS-5 assessment indicates less PTSD symptoms endorsed and a better outcome. Minimum score is 0, maximum score is 20 for PTSD subtotals.	Baseline, 3, 6, 12 months post baseline
Primary	Change in Post-Traumatic Stress Disorder Symptom Checklist for DSM-5 (PCL-5)	Assessing change in PTSD symptom and severity over time. This scale is completed by the participants and a lower score indicates less PTSD symptoms and better study outcomes. Maximum score is 80 and minimum score is 20.	Baseline, every 2 weeks for 12 weeks, 3, 6, 12 months post baseline
Primary	Change in Columbia Suicide Severity Rating Scale (C-SSRS)	Suicide ideation, intensity, and behavior assessment. This is a clinical interview to assess suicide severity. Reduction in suicide related behaviors represents a better study outcome.	Baseline, 3, 6, 12 months post baseline
Primary	Change in Suicide Behavior Questionnaire - Revised (SBQ-R)	Suicide ideation, intensity, and behavior assessment completed by participants. Scores range from 3 to 18, with lower score representing better study outcome.	Baseline, every 2 weeks for 12 weeks, 3, 6, 12 months post baseline
Secondary	Change in Beck Depression Inventory-II	Self report depression checklist. Beck Depression Inventory-II scores range from 0 to 63 and lower score represent better outcome.	Baseline, every 2 weeks for 12 weeks, 3, 6, 12 months post baseline
Secondary	Change in State Trait Anxiety Inventory Form Y	Anxiety symptom checklists ranging from from 20 to 80. Lower scores on this measures represents better study outcome.	Baseline, every 2 weeks for 12 weeks, 3, 6, 12 months post baseline
Secondary	Change in California Verbal Learning Test	Verbal memory task that will be used to measure the change in executive function over time.	Baseline, 3, 6, 12 months post baseline
Secondary	Change in Wisconsin Card Sort Task	Computer task that will be used to measure the change in executive function over time.	Baseline, 3, 6, 12 months post baseline
Secondary	Change in Iowa Gambling Task	Computer task that measure the change in decision making over time.	Baseline, 3, 6, 12 months post baseline
Secondary	Change in General Health Survey (Short form 36)	General health questionnaire to assess change in general health outcomes over time. General health survey is scored from 0 to 100 with a higher score denoting better study outcomes.	Baseline, 3, 6, 12 months post baseline
Secondary	Change in Quality of Life Inventory	Quality of Life assessment to examine change in quality of life over time. Quality of life inventory is scored from 16 to 112, higher score indicating better study outcome.	Baseline, 3, 6, 12 months post baseline
Secondary	Change in Brief Pain Inventory	Brief pain inventory asks participants identify areas on their body causing pain and rate the severity. Less pain symptoms over time represent a better study outcome.	Baseline, 3, 6, 12 months post baseline
Secondary	Exploratory analysis of genetic markers associated with endocannabinoid system	DNA analysis to examine genetic markers associated with the endocannabinoid system. The genetic data will be collected from blood samples during baseline. Data will be grouped based on genetic variants of proteins within the endocannabinoid system to identify genetic differences in response to the treatment trial.	Baseline